Monitoring therapeutic response and resistance with liquid biopsy

Tissue biopsy is the gold standard for diagnosis and morphological and immunohistochemical analyses to characterize cancer. However, tissue biopsy usually requires an invasive procedure, and it can be challenging depending on the condition of the patient and the location of the tumor. Even liquid biopsy analysis of body fluids such as blood, saliva, gastric juice, sweat, tears and cerebrospinal fluid may require invasive procedures to obtain samples. Liquid biopsy can be applied to circulating tumor cells (CTCs) or nucleic acids (NAs) in blood. Recently, urine has gained popularity due to its less invasive sampling, ability to easily repeat samples, and ability to follow tumor evolution in real-time, making it a powerful tool for diagnosis and treatment monitoring in cancer patients. With the development and advancements in extraction methods of urinary substances, urinary NAs have been found to be closely related to carcinogenesis, metastasis, and therapeutic response, not only in urological cancers but also in non-urological cancers. This review mainly highlights the components of urine liquid biopsy and their utility and limitations in oncology, especially in non-urological cancers.

Download Full-text

Inter-eye genomic heterogeneity in bilateral retinoblastoma via aqueous humor liquid biopsy

npj Precision Oncology ◽

10.1038/s41698-021-00212-0 ◽

2021 ◽

Vol 5 (1) ◽

Author(s):

Elyssa Y. Wong ◽

Liya Xu ◽

Lishuang Shen ◽

Mary E. Kim ◽

Ashley Polski ◽

...

Keyword(s):

Aqueous Humor ◽

Liquid Biopsy ◽

Therapeutic Response ◽

Tumor Tissue ◽

Suppressor Gene ◽

Active Management ◽

Similar Treatment ◽

Bilateral Retinoblastoma ◽

Tumor Dna ◽

Therapeutic Responses

AbstractGermline alterations in the RB1 tumor suppressor gene predispose patients to develop retinoblastoma (RB) in both eyes. While similar treatment is given for each eye, there is often a variable therapeutic response between the eyes. Herein, we use the aqueous humor (AH) liquid biopsy to evaluate the cell-free tumor DNA (ctDNA) from each eye in a patient with bilateral RB. Despite the same predisposing germline RB1 mutation, AH analysis identified a different somatic RB1 mutation as well as separate and distinct chromosomal alterations in each eye. The longitudinal alterations in tumor fraction (TFx) corresponded to therapeutic responses in each eye. This case demonstrates that bilateral RB tumors develop separate genomic alterations, which may play a role in tumorigenesis and prognosis for eye salvage. Identifying these inter-eye differences without the need for enucleated tumor tissue may help direct active management of RB, with particular usefulness in bilateral cases.

Download Full-text

Liquid Biopsy to Characterize Cell-Free DNA in Cancer Detection and Monitoring

Research and Development on Information and Communication Technology ◽

10.32913/mic-ict-research.v2019.n2.895 ◽

2019 ◽

Vol 2019 (2) ◽

pp. 93-98

Author(s):

Nguyễn Ngọc Trân

Keyword(s):

Cancer Detection ◽

Liquid Biopsy ◽

Therapeutic Response ◽

Biological Fluids ◽

Genomic Evolution ◽

Paper Briefly ◽

Cell Free Dna ◽

Therapeutic Implications ◽

Free Dna ◽

Prognosis And Prediction

Liquid biopsy, a concept introduced approximately a decade ago, refers to noninvasive approaches that have become the focus of biomedical research. In clinical oncology and research, the term liquid biopsy is used in a broad sense as the sampling and analysis of analytes including cell-free DNA from various accessible biological fluids for diagnosis, prognosis and prediction of a therapeutic response. This technology has the potential to be used in tracking the genomic evolution of tumors over time. It may also have therapeutic implications in terms of its ability to detect actionable events or resistant subclonal populations while avoiding the need to conduct repeated biopsies. This paper briefly reviews the major advances in liquid biopsy assay technologies and discusses the types of cancers that most likely benefit from early detection.

Download Full-text

TKI-Resistenzen beim EGFR-positiven NSCLC

Onkologische Welt ◽

10.1055/a-1013-3722 ◽

2019 ◽

Vol 10 (05) ◽

pp. 216-216

Author(s):

Susanne Krome

Keyword(s):

Liquid Biopsy ◽

Invasives Monitoring ◽

Egfr Tki

EGFR-Tyrosinkinase-Inhibitoren (EGFR-TKI) haben zu einem Paradigmenwechsel in der Behandlungsstrategie für nicht-kleinzellige Bronchialkarzinome (NSCLC) geführt und gehören inzwischen zum Standard. Dabei ist es auch wichtig, primäre und erworbene Resistenzen zu überwinden. Eine aktuelle Studie mit 116 Patienten ergab unterschiedliche Resistenz-Mechanismen für TKI der 1./2. und der 3. Generation. Die Liquid Biopsy ist nach Ansicht der Autoren eine Option für ein nicht-invasives Monitoring der molekularen Veränderungen unter der EGFR-Therapie. Ein Review beschäftigte sich mit den Resistenzmechanismen und der Liquid Biopsy als Instrument für die Therapieplanung und -monitoring.

Download Full-text